Top

17-10-2017 | Colorectal cancer | Article

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

Journal: Cancer Chemotherapy and Pharmacology

Authors: Heinz-Josef Lenz, Philip Philip, Mark Saunders, Tatjana Kolevska, Kalyan Mukherjee, Leslie Samuel, Shailesh Bondarde, Tracy Dobbs, Mary Tagliaferri, Ute Hoch, Alison L. Hannah, Maurice Berkowitz

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). This phase II study compared EP versus irinotecan as second-line treatment for KRAS-mutant, irinotecan-naïve, metastatic colorectal cancer (mCRC).

Methods

Patients were randomized to EP 145 mg/m² or irinotecan 350 mg/m² Q21d until disease progression/unacceptable toxicity. The primary endpoint was progression-free survival (PFS) with response determined by central radiologic review (RECIST version 1.1).

Results

The study was terminated before completing accrual due to evolving standards of care. Eighty-three patients were randomized. Median PFS was longer with EP versus irinotecan (4.0 versus 2.8 months, respectively; HR 0.65; 95% CI 0.40–1.04; P = 0.07). Six-month PFS rates were 32.8 and 15.4%, respectively. Median OS was 9.6 and 8.4 months in EP and irinotecan arms, respectively (HR 0.91; 95% CI 0.56–1.49). ORRs were 10 and 5%, respectively (P = 0.676); median DOR was significantly longer in EP arm (7.9 versus 1.4 months; P = 0.018). The most common grade-3/4 adverse events for EP and irinotecan were diarrhea (21 vs 20%), neutropenia (10 vs 22%), abdominal pain (14 vs 5%), nausea (14 vs 2%), and vomiting (12 vs 7%), respectively.

Conclusion

EP is active and safe for second-line treatment of KRAS-mutant, irinotecan-naïve mCRC.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefPubMed

Surveillance, epidemiology, and end results program: SEER stat facts sheet: colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html. Cited 8 Feb 2017

Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ et al (2015) A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 14:1–10CrossRefPubMed

National Comprehensive Cancer Network: clinical practice guidelines in oncology (NCCN guidelines^®): colon cancer version 1.2017, 11/16 update. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Cited 8 Feb 2017

Lucas AS, O’Neil BH, Goldberg RM (2011) A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 10:238–244CrossRefPubMed

Cunningham D, Pyrhönen S, James R, Hickish TF, Heikkila R et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418CrossRefPubMed

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412CrossRefPubMed

André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP et al (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35:1343–1347CrossRefPubMed

Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807–814CrossRefPubMed

10.

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786CrossRefPubMed

11.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C et al (2007) on behalf of Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676CrossRefPubMed

12.

Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH Jr, Bodoky G et al (2008) Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 26:4544–4550CrossRefPubMed

13.

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506CrossRefPubMed

14.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609–1618CrossRefPubMed

15.

Kawato Y, Animimi M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187–4191PubMed

16.

Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR et al (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22:2849–2855CrossRefPubMed

17.

Kehrer DFS, Yamamoto W, Verweij J, de Jonge MJA, de Bruijn P, Sparreboom A (2000) Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 6:3451–3458PubMed

18.

Masi G, Falcone A, Di Paolo A, Allegrini G, Danesi R, Barbara C et al (2004) A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. Clin Cancer Res 10:1657–1663CrossRefPubMed

19.

Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA et al (2000) Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 18:659–667CrossRefPubMed

20.

Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH et al (1999) Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 17:1897–1905CrossRefPubMed

21.

Chabot CG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245–259CrossRefPubMed

22.

Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C et al (2000) Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6:2236–2244PubMed

23.

Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y (1995) Topoisomerase I related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55:2116–2121PubMed

24.

Hoch U, Staschen C-M, Johnson RK, Eldon MA (2014) Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 74:1125–1137CrossRefPubMedPubMedCentral

25.

Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK et al (2015) NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer 15:685. doi:10.1186/s12885-015-1672-4 CrossRefPubMedPubMedCentral

26.

Persson H, Barker T, Eldon M et al (2008) NKTR-102, a novel pegylated-irinotecan, has an enhanced pharmacokinetic profile with reduced gastrointestinal and hematopoietic toxicity compared to irinotecan with repeat dosing in dogs. In: Presented at the 2008 American Association for Cancer Research Annual Meeting, San Diego, 12–16 April (abstr 5741)

27.

Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M et al (2013) A multicenter, phase 1, open-label, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19:268–278CrossRefPubMed

28.

Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D et al (2013) Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol 10:4060–4066CrossRef

29.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, NKTR-102 Study Group et al (2013) Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol 14:1216–1225CrossRefPubMed

30.

Perez EA, Awada A, O’Shaughnessy J, Rugo HS, Twelves C, Im SA et al (2015) Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16:1556–1568CrossRefPubMed

31.

Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA et al (2016) Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. Springerplus 5:1033CrossRefPubMedPubMedCentral

32.

Krishnamurthi S, Manpreet C, Rodal MB et al (2014) A phase 1 study of etirinotecan pegol in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. J Clin Oncol 32(suppl 3) (abstr 550)

33.

Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O et al (2016) PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med 5:676–683CrossRefPubMedPubMedCentral